Allergan settlement with end-payors in US antitrust case over Restasis gets final approval
MLex Summary: Allergan’s $30 million settlement with end-payor purchasers of Restasis has been granted final approval by a US judge, resolving allegations the company illegally blocked generic competition for the dry-eye medication.See...To view the full article, register now.
Already a subscriber? Click here to view full article